Effects of Volatile Anesthetics on Proliferation and Viability of SW480 Colon Cancer Cells In Vitro

Abstract

Background/Aim: For patients undergoing cancer surgery, the risk for cancer progression is enhanced during the perioperative period. To what extent the type of anesthetic can affect the metastatic process and finally the outcome of patients with cancer is under debate. For this reason, the aim of this study was to investigate the effects of the volatile anesthetics sevoflurane and desflurane on colon cancer cells in vitro. Materials and Methods: SW480 colon carcinoma cells were exposed for 3 or 6 h to sevoflurane (1 or 2.5 vol%) or desflurane (6 or 12 vol%). Cell cycle distribution was analyzed by flow cytometry after a 24-72 h recovery and apoptosis was detected by annexin V staining after a 0-48 h recovery. Viability was tested by measuring ATP content after 0 and 24 h recovery. Results: Treatment with sevoflurane or desflurane caused no or only slight changes in cell-cycle distribution and apoptosis rate. Desflurane at 12vol% significantly reduced cell viability by 17±25% and 11±22% after 3 and 6 h incubation and 24 h recovery, respectively, while 2.5 vol% sevoflurane slightly increased viability. Conclusion: At clinically relevant concentrations, sevoflurane and desflurane had only slight effects on SW480 colon cancer cells in vitro.

Lidocine potentiates the cytotoxicity of 5‐fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression

“…7,23 Lidocaine had been reported to exert anticancer and chemosensitization effects on cancer therapy. 14,18,20 Considering that lidocaine has few side effects on patient's health, looking for possible antitumor influences of lidocaine will not only be helpful for exploring the other beneficial activity of lidocaine, but provide possible chemosensitization drug for cancer treatment. Study on multiple actions of F I G U R E 5 The activation of PI3K/AKT pathways in choriocarcinoma cells after 5-Fu + lidocaine treatment.…”

“…Firstly, Johnson et al pointed out that lidocaine resulted in local neurotoxicity by inducing mitochondrial dysfunction and activation of apoptosis pathways. Increasing number of reports in recent years revealed that lidocaine displayed anticancer activity on breast cancer, gastric cancer and colon cancer . Moreover, Li et al proved that lidocaine sensitized the cytotoxicity of cisplatin to breast cancer cells via RARβ2 and RASSF1A, which implied that lidocaine might also exert chemosensitization effect on choriocarcinoma.…”

Scutellarin combined with Lidocaine: a new combination of anti-glioma drugs

“…For example, they could be used as a sensitizer for cisplatin. In ovarian cancer [15], non-small cell lung cancer (NSCLC) [16] and prostate cancer [17], Scutellarin interacted with cisplatin to sensitize the response of cancer cells to cisplatin and declined its toxicity. Moreover, Lidocaine suppressed tumor development and enhanced the sensitivity of cisplatin in hepatocellular carcinoma and breast cancer [18,19].…”

“…In recent years, studies have found that Lidocaine exerts anti-tumor effect. Firstly, Lidocaine repressed colon cancer cells proliferation, and induced their cell-cycle arrest and apoptosis by activation of apoptosis protein pathway [16,17]. In addition, Lidocaine inhibited the growth of HepG2 cells in a dose-and time-dependent manner [18].…”

Anesthetics or anesthetic techniques and cancer surgical outcomes: a possible link

“…Yang et al [ 46 ] incubated SW480 colon cells with different concentrations of sevoflurane (1.7%, 3.4% and 5.1%) for 6 h, and the results have shown sevoflurane’s capacity to induce apoptosis and inhibit the proliferation and invasion of colon cancer cells by inactivating the Ras/Raf/MEK/ERK signaling pathway. However, research by Bundscherer et al [ 47 ] had revealed sevoflurane’s and desflurane’s limited effect on SW480 colon cancer cells, albeit at lower concentrations of drug during incubation (1% or 2.5% sevoflurane).…”